Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

• Status: Completed
• Trial end date: 2013-02-21
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the safety, tolerability and efficacy of AQW051 in treating moderate to severe L-dopa induced dyskinesias (movement disorders) in patients with Parkinson's disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Levodopa

Criteria

Inclusion Criteria:

• Patients with Parkinson's disease

• Patients with dyskinesias for at least 3 months

• Patients with moderate to severe dyskinesias

• Patients on L-dopa treatment for at least 3 years

Exclusion Criteria:

• Patients with atypical Parkinson's disease

• Patients who have had prior surgery for Parkinson's disease

• Patients who are cognitively impaired, have psychosis, have confusional states or hallucinate

• Patients who received neuroleptics or anti-psychotics within 2 months

• Women of child-bearing potential

Other protocol-defined inclusion/exclusion criteria may apply.